Fig 1.

The CCRCC patients who respond to sunitinib treatment have a much higher density of FSHR-expressing vessels in the primary tumours, compared with patients who have stable disease or do not respond to the treatment. (A–C) Immunoperoxidase staining (red) for FSHR of paraffin sections from primary tumours removed by surgery. Representative images of tumour sections from responsive (A), stable (B) or non-responsive (C) patients. (D–L) Representative double immunofluorescence images of tumour sections used to determine the percentage of FSHR-positive vessels. Paraffin sections from primary tumours have been stained with antibodies against vWF and FSHR, followed by fluorescently labelled green and red, respectively, secondary antibodies. Tumour sections from patients responsive to sunitinib treatment (D–F), stable (G–I) or non-responsive (J–L). The arrows point to blood vessels. Bar: 20 μm.